What is Deepcell?
Deepcell is at the forefront of precision medicine, leveraging a unique combination of artificial intelligence, cell classification, and single-cell analysis to provide unprecedented views of cell biology. Founded in 2017, the company has developed proprietary microfluidics-based technology powered by continuously learning AI. This technology enables unbiased cell classification based on detailed visual features and sorting, while crucially maintaining cell viability for downstream analysis. The Deepcell platform can isolate virtually any cell type, even those present at extremely low frequencies, making it a powerful tool for translational research, diagnostics, and therapeutic development.
How much funding has Deepcell raised?
Deepcell has raised a total of $93M across 2 funding rounds:
Series A
$20M
Series B
$73M
Series A (2020): $20M with participation from Bow Capital, Andreessen Horowitz, Jeff Dean, Stanford University, 50Y, and DCVC
Series B (2022): $73M led by Koch Disruptive Technologies, Bridger Healthcare, Casdin Capital, and Horizons Ventures
Key Investors in Deepcell
Bow Capital
Bow Capital is a venture capital fund that connects academia, business, and technology, leveraging its unique partnership with the University of California to access a vast talent pool. The firm provides entrepreneurs with unparalleled access to a network of Silicon Valley founders and industry leaders, facilitating innovation and growth.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for its investments in technology startups. The firm provides not only capital but also strategic guidance and operational support to its portfolio companies, often focusing on disruptive technologies and market leaders.
DCVC
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems. The company focuses on leveraging artificial intelligence to unlock potential across various sectors, including energy, biotechnology, and agriculture.
What's next for Deepcell?
With its recent major strategic investment, Deepcell is poised for accelerated growth and market expansion. The substantial capital infusion, particularly following its Series B financing, suggests a strategic focus on scaling operations, enhancing its AI-driven platform, and broadening its service offerings in translational research and diagnostics. The company's ability to isolate rare cells and maintain viability positions it as a key player in the rapidly evolving fields of precision medicine and single-cell genomics. Future developments are likely to center on further refining its AI algorithms and expanding its application in therapeutic development and clinical diagnostics.
See full Deepcell company page
